Bright Green To Supply DEA-Approved Cannabis Extracts And Psychedelics To FDA-Registered Pharmaceutical Company
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2024
0mins
Should l Buy ?
Source: Benzinga
Bright Green Corporation's Supply Agreement: Bright Green Corporation has signed a letter of intent to supply DEA-approved cannabis extracts and plant-based psychedelics to Benuvia Operations, which is FDA-registered and DEA-licensed, for clinical use in pharmaceutical manufacturing.
Regulatory Approvals and Future Plans: The company has received final approval from the New Mexico Board of Pharmacy and the DEA for Schedule I and II substances, positioning itself as a leading supplier of plant-based raw materials for cannabinoid, psychedelic, and opioid-based drugs in the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
